An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

  • Barosi G
  • Agarwal M
  • Zweegman S
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Abstract 2844

Cite

CITATION STYLE

APA

Barosi, G., Agarwal, M., Zweegman, S., Willenbacher, W., Pakstyte, S., Raymakers, R., … Harrison, C. N. (2012). An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF). Blood, 120(21), 2844–2844. https://doi.org/10.1182/blood.v120.21.2844.2844

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free